Cocrystal Pharma, Inc.
COCPHealthcareNASDAQBiotechnology · Last scanned Oct 23, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cocrystal Pharma, Inc. (COCP) is listed under Biotechnology. At a $17.6M market cap, Cocrystal Pharma, Inc. ranks as a micro-cap company within healthcare. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Market Cap
$17.6M
Beta
1.48
P/E (TTM)
—
P/E (Fwd)
-1.92
EPS (TTM)
$-0.77
EPS (Fwd)
$-0.47
ROE
-311.7%
ROA
-96.1%
Cash
$2.2M
Total Debt
$1.3M
Free CF
-$4.3M
52W Change
-14.1%
Annual Financials
Cash vs Debt
Where COCP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, COCP finished 16.67% below its 150-day moving average ($1.14) and 14.41% below its 200-day moving average ($1.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COCP overbought or oversold?
At the October 20, 2026 close, COCP's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.2M in cash and $1.3M in debt, COCP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$4.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -311.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing COCP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.